StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Design Therapeutics's enterprise value was $466.59M on Nov 11, 2026, against $328.89M a year earlier. Over the last 5 years it ranged from -$188.90M to $788.64M, with a median of $98.62M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$466.59M+42.1%
2025Dec 31, 2025$328.32M+244.7%
2024Dec 31, 2024$95.25M–
2023Dec 29, 2023-$142.51M-162.3%
2022Dec 30, 2022$228.72M-71.0%
2021Dec 31, 2021$788.64M–

More Design Therapeutics figures

See a number that looks wrong?